About Epsilen Bio
Epsilen Bio is a Healthcare company based in Milano (Italy) founded in 2019 by Angelo Lombardo and Luigi Naldini, and was acquired by Chroma Medicine in November 2021. Epigenetic gene silencing technologies are developed for disease treatments. Its chief executive, as recorded, is Julia Berretta. Epsilen Bio offers products and services including Epigenetic Silencing. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms.
Company details
Founded in 2019 in Milano, Italy, Epsilen Bio operates in the biotechnology sector, where therapies are developed using Epigenetic Transcriptional Repressors (ETRs) for gene silencing. These approaches target inherited genetic diseases, cancer, autoimmune conditions, degenerative disorders, and viral infections. Operations focus on advancing clinical applications through innovative epigenetic mechanisms, with leadership provided by co-founders Angelo Lombardo and Luigi Naldini, alongside CEO Julia Berretta.
- Headquarters Milano, Italy
- Founders Angelo Lombardo, Luigi Naldini
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website epsilenbio.com
- Acquired by Chroma Medicine (Nov 2021)
- InvestorsChroma Medicine
& 1 more
- Acquired byChroma Medicine
(Nov 2021)
Products & Services of Epsilen Bio
Epsilen Bio offers a comprehensive portfolio of products and services, including Epigenetic Silencing.
Method to treat human diseases via epigenetic techniques.
Funding Insights of Epsilen Bio
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Epsilen Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | Seed | β | Sofinnova Partners | β |
2 investors in total: 2 institutional.
Investors in Epsilen Bio
Epsilen Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Chroma Medicine and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sofinnova Partners is focused on life sciences and healthcare investments. | sofinnovapartners.com | Paris, France | ||
Epigenetic editing platform is developed for genomic medicines. | 2020 | chromamedicine.com | Cambridge, United States |
Investor details for Epsilen Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Epsilen Bio
26 people are tracked at Epsilen Bio (8 in leadership, 8 in board & advisors, 10 in team).
| Name | Role | Group |
|---|---|---|
Angelo Lombardo | Co-Founder | Leadership |
Luigi Naldini | Co-Founder | Leadership |
Julia Berretta | CEO | Leadership |
Sivan Harel | Director, Translational Biomarkers & Bioanalytics | Leadership |
Cecilia Fernandez | VP, Strategic Planning & Operations | Leadership |
Tobias Brambrink | VP, Intellectual Property | Leadership |
Sahar Abubucker | VP, Data Sciences | Leadership |
Adam Connelly | Director Of Quality Control | Leadership |
Howard Chang | Advisor | Board & advisors |
Luke Gilbert | Founder | Board & advisors |
J. Keith Joung | Founder | Board & advisors |
Jonathan Weissman | Founder | Board & advisors |
Ahmad Khalil | Advisor | Board & advisors |
David Liu | Founder | Board & advisors |
Bradley Bernstein | Advisor | Board & advisors |
Paula Cannon | Advisor | Board & advisors |
Melissa Pannone | Associate Scientist I | Team |
Kyle Runckel | Scientist II | Team |
Hasit Lunagaria | SVP, People & Culture | Team |
Lenka Kundrat Hoffman | Principal Scientist | Team |
6 more people are available in the full profile.
Complete people profiles for Epsilen Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Epsilen Bio
3 dated milestones of Epsilen Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Epsilen Bio is founded.
- Funding First funding round.
- Exit Acquired by Chroma Medicine.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Epsilen Bio
Complete news archive for Epsilen Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epsilen Bio
Epsilen Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Epsilen Bio is headquartered in Milano, Italy.
Julia Berretta is the CEO of Epsilen Bio, as recorded in our data.
Founded in 2019 in Milano, Italy, Epsilen Bio operates in the biotechnology sector, where therapies are developed using Epigenetic Transcriptional Repressors (ETRs) for gene silencing. These approaches target inherited genetic diseases, cancer, autoimmune conditions, degenerative disorders, and viral infections. Operations focus on advancing clinical applications through innovative epigenetic mechanisms, with leadership provided by co-founders Angelo Lombardo and Luigi Naldini, alongside CEO Julia Berretta.
Epsilen Bio offers Epigenetic Silencing.
Epsilen Bio has 2 investors. Key investors include Chroma Medicine, and Sofinnova Partners.
Yes. Epsilen Bio was acquired by Chroma Medicine in November 2021.

